Sequences tumors from high-risk solid tumor and hematological malignancy patients in collaboration with Ashion Analytics, a Certified Authorization Professional (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical genomics testing laboratory based in Phoenix, AZ.
The program recognizes that a larger than expected number of children with cancer have mutations in genes that lead to an increased risk of developing cancer.
Since 2001, the Aflac Cancer Center has offered its multidisciplinary Cancer Survivorship Program to address the unique needs of childhood cancer survivors who are approximately two years off therapy.
Our Cell and Gene Therapeutics Program is focused on the development and implementation of novel gene therapy treatments for childhood cancers and bleeding disorders.
The Developmental Therapeutics Program focuses on finding new and innovative treatments for children with cancer. Our team develops conducts, and leads local and National Phase I and Phase II trials for children with recurrent and/or high-risk oncologic disease.
We offer comprehensive diagnosis and treatment for a wide spectrum of rare childhood blood disorders, such as immune thrombocytopenia and other platelet disorders, white blood cell disorders, bone marrow failure syndromes, and congenital and acquired anemias.
In collaboration with Emory University, we follow more than 1,000 children and adults with bleeding disorders and approximately 200 with clotting disorders in our Comprehensive Hemostasis and Thrombosis Program.
Our program offers a large team of providers with specialized expertise in treating all forms of leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and non-Hodgkin lymphoma (NHL).
We have one of the leading pediatric brain tumor programs in the country, and we follow more than 750 children and young adults with brain tumors each year.
Our Sickle Cell Disease Program offers comprehensive clinics, transfusion services, specialty clinics and inpatient care. In addition, we have innovative services and technology for sickle cell disease, such as transcranial Doppler (TCD) screening to evaluate patients for stroke risk and BMT for eligible candidates.
Our Solid Tumor Program is made up of medical and research professionals dedicated to treating solid tumors and developing new treatments and cures for the future.
